Page last updated: 2024-11-12

ginsenoside ro

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ginsenoside Ro: from ginseng; RN given refers to ginsenoside Ro, (all-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11815492
CHEMBL ID488317
CHEBI ID67981
SCHEMBL ID22761640
MeSH IDM0177360

Synonyms (32)

Synonym
chikusetsusaponin 5
beta-d-glucopyranosiduronic acid, (3beta)-28-(beta-d-glucopyranosyloxy)-28-oxoolean-12-en-3-yl 2-o-beta-d-glucopyranosyl-
ginsenoside ro
chikusetsusaponin v
C17543
34367-04-9
chebi:67981 ,
ginsenoside r0
CHEMBL488317
chikusetsusaponin-v
unii-of1plt74q8
of1plt74q8 ,
ginsenoside-ro
S9103
28-o-glucopyranosyl-3-o-glucopyranosyl-1''-2'-glucopyranosyloleanate
AKOS015893912
CS-3828
AC-34669
Q-100416
HY-N0607
saponin v
hericiumsaponin s3
.beta.-d-glucopyranosiduronic acid, (3.beta.)-28-(.beta.-d-glucopyranosyloxy)-28-oxoolean-12-en-3-yl 2-o-.beta.-d-glucopyranosyl-
Q27136466
ginsenosidero
CCG-270592
(2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2s,3r
6-[[4,4,6a,6b,11,11,14b-heptamethyl-8a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
DTXSID401317177
SCHEMBL22761640
AS-82743
G0586

Research Excerpts

Actions

Ginsenoside Ro inhibited the increase of connective tissue in the liver of CCl4-induced chronic hepatitic rats. The drug did not suppress a developing adjuvant-induced edema in arthritic rats.

ExcerptReferenceRelevance
"Ginsenoside Ro inhibited the increase of connective tissue in the liver of CCl4-induced chronic hepatitic rats."( Anti-hepatitic activity of ginsenoside Ro.
Kubo, M; Matsuda, H; Samukawa, K, 1991
)
1.3
"Ginsenoside Ro did not suppress a developing adjuvant-induced edema in arthritic rats."( Anti-inflammatory activity of ginsenoside Ro.
Kubo, M; Matsuda, H; Samukawa, K, 1990
)
1.29

Pharmacokinetics

ExcerptReferenceRelevance
" The method was validated and successfully applied to the preliminary pharmacokinetic study of chikusetsusaponin V and chikusetsusaponin IV in rat plasma after oral administration of saponins extracted from Rhizoma Panacis Japonici."( Determination of chikusetsusaponin V and chikusetsusaponin IV in rat plasma by liquid chromatography-mass spectrometry and its application to a preliminary pharmacokinetic study.
Chen, J; Li, F; Qi, D; Shi, X; Yang, X; Yang, Z; Zhang, C, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of 29 was significantly improved in comparison with its aglycon."( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoid saponinA terpene glycoside in which the terpene moiety is a triterpenoid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ginsenosides biosynthesis225

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1441288Inhibition of hyaluronidase (unknown origin) using hyaluronic acid as substrate preincubated for 20 mins followed by substrate addition measured after 40 mins by colorimetric method2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Discovery of hyaluronidase inhibitors from natural products and their mechanistic characterization under DMSO-perturbed assay conditions.
AID1466835Inhibition of human amyloid beta (1 to 40) aggregation assessed as aggregation level at 25 uM after 24 hrs by Th-T fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Inhibition of amyloid β aggregation and protective effect on SH-SY5Y cells by triterpenoid saponins from the cactus Polaskia chichipe.
AID334335Induction of morphological transformation of rat ASK cells into astrocytes at 100 ug/ml after 1 hr by light microscopy
AID1728066Activation of AMPK in human Huh-7 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 12 hrs by Western blot analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (9.38)18.2507
2000's3 (9.38)29.6817
2010's22 (68.75)24.3611
2020's4 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.60 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]